GH Secretagogues FDA Approved

Tesamorelin

Also known as: Egrifta

Molecular Identifiers

Molecular Formula

C221H366N72O67S

PubChem CID

16137828

Overview

GHRH analog focused on visceral fat reduction. Studies demonstrate significant abdominal fat reduction. Sustained GH elevation with daily administration.

FDA-approved as Egrifta (2010) for reduction of excess abdominal fat (lipodystrophy) in HIV patients on antiretroviral therapy.

Sequence (1 letter): YADAIFTSSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL
Extended notation: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Ser-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu

Half-life

~26-38 minutes

Administration Route

Subcutaneous

Category

GH Secretagogues

Mechanism of Action

  • Modified GHRH analog
  • Potent and sustained stimulation of GH secretion
  • Selective visceral fat reduction
  • IGF-1 elevation

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 1-2 mg per injection
Frequency Once daily
Timing Morning, fasting
Duration 12-24 weeks

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Injection site reactions
  • Arthralgia
  • Peripheral edema
  • Myalgia
  • Pruritus

Presentations & Preparation

Vials of Tesamorelin found in the research market:

2 mg5 mg20 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: 2 ml per 2 mg vial
  • Slowly inject the diluent against the vial wall
  • Gently swirl until fully dissolved
  • Never shake

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (up to 30 days)
  • Protect from direct light
  • Do not freeze after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on Tesamorelin.

2010 · N Engl J Med

Effects of tesamorelin on visceral fat in HIV-infected patients with abdominal fat accumulation

Falutz J, Allas S, Blot K, et al.
2012 · Drugs

Tesamorelin reduces visceral fat and improves metabolic parameters in HIV-infected patients

Stanley TL, Grinspoon SK

Related Peptides

CJC-1295 with DAC

1-2 mg per week · Once per week

CJC-1295 sem DAC

100-200 mcg per injection · 2-3 times daily

GHRP-2

100-300 mcg per injection · 2-3 times per day

GHRP-6

100-300 mcg per injection · 2-3 times per day

Hexarelin

200-300 mcg per injection · 2-3 times per day

Ipamorelin

200-300 mcg per injection · 2-3 times daily